Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement

Claudio Marcassa, Jeroen J. Bax, Frank Bengel, Birger Hesse, Claus L. Petersen, Eliana Reyes, Richard Underwood

Research output: Contribution to journalArticle

Abstract

Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalEuropean Heart Journal
Volume29
Issue number4
DOIs
StatePublished - Feb 2008

Fingerprint

Myocardial Perfusion Imaging
Perfusion Imaging
Cost-Benefit Analysis
Coronary Artery Disease
Safety
Practice Guidelines
Developing Countries
Cause of Death
Myocardial Infarction
Costs and Cost Analysis
Mortality
Therapeutics

Keywords

  • Coronary artery disease
  • Cost-effectiveness
  • Myocardial perfusion scintigraphy
  • Radionuclide
  • Scintigraphy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Marcassa, C., Bax, J. J., Bengel, F., Hesse, B., Petersen, C. L., Reyes, E., & Underwood, R. (2008). Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement. European Heart Journal, 29(4), 557-563. https://doi.org/10.1093/eurheartj/ehm607

Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy : A position statement. / Marcassa, Claudio; Bax, Jeroen J.; Bengel, Frank; Hesse, Birger; Petersen, Claus L.; Reyes, Eliana; Underwood, Richard.

In: European Heart Journal, Vol. 29, No. 4, 02.2008, p. 557-563.

Research output: Contribution to journalArticle

Marcassa, C, Bax, JJ, Bengel, F, Hesse, B, Petersen, CL, Reyes, E & Underwood, R 2008, 'Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement', European Heart Journal, vol. 29, no. 4, pp. 557-563. https://doi.org/10.1093/eurheartj/ehm607
Marcassa, Claudio ; Bax, Jeroen J. ; Bengel, Frank ; Hesse, Birger ; Petersen, Claus L. ; Reyes, Eliana ; Underwood, Richard. / Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy : A position statement. In: European Heart Journal. 2008 ; Vol. 29, No. 4. pp. 557-563.
@article{43c6d5f486c54228a005d7e90c04ea61,
title = "Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement",
abstract = "Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.",
keywords = "Coronary artery disease, Cost-effectiveness, Myocardial perfusion scintigraphy, Radionuclide, Scintigraphy",
author = "Claudio Marcassa and Bax, {Jeroen J.} and Frank Bengel and Birger Hesse and Petersen, {Claus L.} and Eliana Reyes and Richard Underwood",
year = "2008",
month = "2",
doi = "10.1093/eurheartj/ehm607",
language = "English (US)",
volume = "29",
pages = "557--563",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy

T2 - A position statement

AU - Marcassa, Claudio

AU - Bax, Jeroen J.

AU - Bengel, Frank

AU - Hesse, Birger

AU - Petersen, Claus L.

AU - Reyes, Eliana

AU - Underwood, Richard

PY - 2008/2

Y1 - 2008/2

N2 - Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.

AB - Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.

KW - Coronary artery disease

KW - Cost-effectiveness

KW - Myocardial perfusion scintigraphy

KW - Radionuclide

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=39349089910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39349089910&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehm607

DO - 10.1093/eurheartj/ehm607

M3 - Article

C2 - 18202253

AN - SCOPUS:39349089910

VL - 29

SP - 557

EP - 563

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 4

ER -